As migraine research continues to evolve, driven by increasing patient demand and a growing therapeutic pipeline, DelRicht Research stands out as a trusted partner for sponsors and CROs seeking both speed and precision. With more than 19 migraine trials completed over the past eight years, 740+ participants enrolled, and 17 experienced sites nationwide, our network consistently delivers high-quality outcomes across complex and time-sensitive protocols.

Trusted Investigators Nationwide

DelRicht’s embedded model ensures that every migraine study is supported by experienced principal investigators who understand the nuances of diagnosis, attack variability, and treatment response. Across our network, investigators bring deep expertise not only in migraine, but across general medicine indications including fibromyalgia, osteoarthritis, gout, obesity, diabetes, and vaccines. This breadth of experience strengthens protocol execution and allows for more comprehensive patient care throughout the study lifecycle.

Integrated Patient Support for Retention and Compliance

Migraine trials require rigorous tracking, timely reporting, and strong patient adherence. DelRicht’s full-time, dedicated site teams support participants at every step, from real-time informed consent through ongoing education and diary compliance. This hands-on approach has driven an average 87.5% diary compliance rate and 88.4% retention rate across studies. Through proactive patient engagement and rapid follow-up, we ensure consistent participation and high-quality data capture, even in trials with complex endpoints and frequent reporting requirements.

Network Capabilities at Scale

With 17 fully equipped sites embedded within high-volume physician practices, DelRicht offers seamless scalability without compromising quality. Each location is supported by robust infrastructure, including secure investigational product storage, access to local laboratories, and onsite specialty care providers. Our centralized start-up and regulatory teams enable efficient study activation, ensuring sponsors can move quickly from site selection to first patient in.

Proven Access to Priority Migraine Cohorts

DelRicht’s embedded site model provides direct access to diverse and high-value patient populations. Our teams routinely recruit across acute, episodic, preventive, and chronic migraine cohorts, ensuring alignment with a wide range of study designs. With an average of 45%+ diversity across our trials, we are committed to inclusive enrollment that reflects real-world patient populations and supports more generalizable outcomes.

Performance That Moves Medicine Forward

Our performance in migraine research speaks for itself. Over the past five years, five of our sites have achieved top enroller status in migraine trials, contributing to the successful advancement of multiple therapies. DelRicht has supported five FDA approvals in the migraine space, including treatments such as Nurtec ODT®, VYEPTI®, Zavzpret®, and Atzumi®. Backed by 17 experienced investigators and more than 320 years of collective principal investigator experience, our teams consistently deliver the scale, speed, and quality sponsors depend on.

Ready to Accelerate Your Next Migraine Trial

DelRicht Research is purpose-built for partnership, combining therapeutic expertise, operational excellence, and broad patient access to accelerate migraine trials from start-up through closeout. If you’re seeking a reliable, high-performing site network to support your next migraine study, our team is ready to help you move medicine forward.